31st Dec 2018 11:30
For release: 31 December 2018
genedrive plc ("genedrive" or the "Company")
Result of AGM
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that at the Annual General Meeting, held today, all resolutions proposed were duly passed.
- Ends -
For further details please contact:
genedrive plc | +44 (0)161 989 0245 |
David Budd: CEO | |
Matthew Fowler: CFO | |
Peel Hunt LLP | |
James Steel | +44 (0)207 418 8900 |
Oliver Jackson | |
Stanford Capital Partners Limited | +44 (0)203 815 8880 |
Patrick Claridge | |
John Howes | |
Consilium Strategic Communications | +44 (0)203 709 5700 |
Chris Gardner | |
Matthew Neal | |
Laura Thornton |
Notes to Editors
About genedrive plc
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® HCV-ID test has received CE-IVD Certification and has been launched in Africa and Asia Pacific. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA and SE Asia (ex-India), and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive® HCV-ID Kit and Genedrive® platform in India. Further details can be found at: www.genedriveplc.com and www.genedrive.com. The Company also has tests in development for tuberculosis (mTB) and Antibiotic Induced Hearing Loss (AIHL).
Related Shares:
Genedrive